Emily J. Hanan

Emily J. Hanan

Auto-generated profile, based on publicly available information

Emily J. Hanan

Department of Discovery Chemistry, Genentech, Inc., South San Francisco, California 94080, United States

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EHEmily J. Hanan
Emily J. Hanan
MBMarie-Gabrielle Braun
Marie-Gabrielle Braun
RHRobert A. Heald
Robert A. Heald
CMCalum MacLeod
Calum MacLeod
CCConnie Chan
Connie Chan
SSSteven T. Staben
Steven T. Staben

20 September 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KSKyung W. Song
Kyung W. Song
KEKyle A. Edgar
Kyle A. Edgar
EHEmily J. Hanan
Emily J. Hanan
MHMarc Hafner
Marc Hafner
JOJason Oeh
Jason Oeh
LFLori S. Friedman
Lori S. Friedman
PIK3CA is one of the most frequently mutated oncogenes; the p110a protein it encodes plays a central role in tumor cell proliferation. Small-molecule inhibitors targeting the PI3K p110a catalytic subunit have entered clinical trials, with early-phase GDC-0077 studies showing antitumor activity and a manageable safety profile in patients with PIK3CA-mutant breast cancer. However, preclinical studies have shown that PI3K pathway inhibition releases negative feedback and activates receptor tyrosine kinase signaling, reengaging the pathway and attenuating drug activity. Here we discover that GDC-0077 and taselisib more potently inhibit mutant PI3K pathway signaling and cell viability through unique HER2-dependent mutant p110a degradation. Both are more effective than other PI3K inhibitors at maintaining prolonged pathway suppression. This study establishes a new strategy for identifying inhibitors that specifically target mutant tumors by selective degradation of the mutant oncoprotein and provide a strong rationale for pursuing PI3Kα degraders in patients with HER2-positive breast cancer. Significance: The PI3K inhibitors GDC-0077 and taselisib have a unique mechanism of action; both inhibitors lead to degradation of mutant p110a protein. The inhibitors that have the ability to trigger specific degradation of mutant p110a without significant change in wild-type p110a protein may result in improved therapeutic index in PIK3CA-mutant tumors. See related commentary by Vanhaesebroeck et al., p. 20. This article is highlighted in the In This Issue feature, p. 1

12 August 2020 in Nature
Verified
Journal Article
Closed access
PDF file
TCThomas Clairfeuille
Thomas Clairfeuille
KBKerry R. Buchholz
Kerry R. Buchholz
QLQingling Li
Qingling Li
EVErik Verschueren
Erik Verschueren
PLPeter Liu
Peter Liu
SRSteven Rutherford
Steven Rutherford

20 November 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
EHEmily J. Hanan
Emily J. Hanan
CECharles Eigenbrot
Charles Eigenbrot
MBMarian C. Bryan
Marian C. Bryan
DBDaniel J. Burdick
Daniel J. Burdick
BCBryan K. Chan
Bryan K. Chan
THTimothy P. Heffron
Timothy P. Heffron
Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients. Approximately 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M). Due to dose-limiting toxicities associated with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-containing EGFR mutants with selectivity over wtEGFR. We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors. X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-containing mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochemical properties.

14 October 2010 in Synlett
Verified
Journal Article
Closed access
PDF file
EHEmily Hanan
Emily Hanan
BCBryan Chan
Bryan Chan
AEAnthony Estrada
Anthony Estrada
DSDaniel Shore
Daniel Shore
JLJoseph Lyssikatos
Joseph Lyssikatos
A one-pot procedure for the conversion of aromatic and heteroaromatic 2-nitroamines into bicyclic 2H-benzimidazoles is described. The procedure employs formic acid, iron powder, and an additive such as NH4Cl to reduce the nitro group and effect the imidazole cyclization with high-yielding conversions generally within one to two hours. The compatibility with a wide range of functionality demonstrates the general utility of this procedure.

1 October 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KGKeira Garland
Keira Garland
HPHomer Pantua
Homer Pantua
MBMarie-Gabrielle Braun
Marie-Gabrielle Braun
DBDaniel J. Burdick
Daniel J. Burdick
GCGeorgette M. Castanedo
Georgette M. Castanedo
EHEmily J. Hanan
Emily J. Hanan